Baric R S, Sullivan E, Hensley L, Yount B, Chen W
Department of Epidemiology, Program in Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
J Virol. 1999 Jan;73(1):638-49. doi: 10.1128/JVI.73.1.638-649.1999.
Persistent infection with mouse hepatitis virus (MHV) strain A59 in murine DBT (delayed brain tumor) cells resulted in the emergence of host range variants, designated V51A and V51B, at 210 days postinfection. These host range mutants replicated efficiently in normally nonpermissive Chinese hamster ovary (CHO), in human hepatocarcinoma (HepG2), and to a lesser extent in human breast carcinoma (MCF7) cell lines. Little if any replication was noted in baby hamster kidney (BHK), green African monkey kidney (COS-7), feline kidney (CRFK), and swine testicular (ST) cell lines. By fluorescent antibody (FA) staining, persistent viruses V10B and V30B, isolated at days 38 and 119 days postinfection, also demonstrated very low levels of replication in human HepG2 cells. These data suggest that persistence may rapidly select for host range expansion of animal viruses. Pretreatment of HepG2 cells with a polyclonal antibody directed against human carcinoembryonic antigens (CEA) or with some monoclonal antibodies (Col-1, Col-4, Col-12, and Col-14) that bind human CEA significantly inhibited V51B infection. Under identical conditions, little or no blockade was evident with other monoclonal antibodies (kat4c or Col-6) which also bind the human CEA glycoproteins. In addition, an antibody (EDDA) directed against irrelevant antigens did not block V51B replication. Pretreatment with the Col-4 and Col-14 antibodies did not block Sindbis virus replication in HepG2 cells or MHV infection in DBT cells, suggesting that one or more CEA glycoproteins likely functioned as receptors for V51B entry into human cell lines. To test this hypothesis, the human biliary glycoprotein (Bgp) and CEA genes were cloned and expressed in normally nonpermissive BHK cell lines by using noncytopathic Sindbis virus replicons (pSinRep19). By growth curves and FA staining, human CEA and to a much lesser extent human Bgp functioned as receptors for V51B entry. Furthermore, V51B replication was blocked with polyclonal antiserum directed against human CEA and Bgp. Under identical conditions, the parental MHV strain A59 failed to replicate in BHK cells expressing human Bgp or CEA. These data suggest that MHV persistence may promote virus cross-species transmissibility by selecting for virus variants that recognize phylogenetic homologues of the normal receptor.
鼠源DBT(延迟性脑肿瘤)细胞持续感染小鼠肝炎病毒(MHV)A59毒株,在感染后210天出现了宿主范围变异株,命名为V51A和V51B。这些宿主范围突变株能在通常不允许其复制的中国仓鼠卵巢(CHO)细胞、人肝癌(HepG2)细胞中高效复制,在人乳腺癌(MCF7)细胞系中的复制效率稍低。在幼仓鼠肾(BHK)细胞、非洲绿猴肾(COS - 7)细胞、猫肾(CRFK)细胞和猪睾丸(ST)细胞系中几乎没有观察到复制现象。通过荧光抗体(FA)染色发现,在感染后第38天和第119天分离得到的持续性病毒V10B和V30B,在人HepG2细胞中的复制水平也非常低。这些数据表明,持续性感染可能会迅速促使动物病毒的宿主范围扩大。用针对人癌胚抗原(CEA)的多克隆抗体或一些能与人CEA结合的单克隆抗体(Col - 1、Col - 4、Col - 12和Col - 14)预处理HepG2细胞,可显著抑制V51B感染。在相同条件下,其他也能与人CEA糖蛋白结合的单克隆抗体(kat4c或Col - 6)几乎没有明显的阻断作用。此外,针对无关抗原的抗体(EDDA)不会阻断V51B的复制。用Col - 4和Col - 14抗体预处理不会阻断辛德毕斯病毒在HepG2细胞中的复制或MHV在DBT细胞中的感染,这表明一种或多种CEA糖蛋白可能作为V51B进入人细胞系的受体。为验证这一假设,通过使用非细胞病变性辛德毕斯病毒复制子(pSinRep19),将人胆汁糖蛋白(Bgp)和CEA基因克隆并在通常不允许其复制的BHK细胞系中表达。通过生长曲线和FA染色发现,人CEA以及程度低得多的人Bgp可作为V51B进入细胞的受体。此外,针对人CEA和Bgp的多克隆抗血清可阻断V51B的复制。在相同条件下,亲本MHV A59毒株在表达人Bgp或CEA的BHK细胞中无法复制。这些数据表明,MHV的持续性感染可能通过选择识别正常受体系统发育同源物的病毒变异株来促进病毒的跨物种传播能力。